Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Minimal Residual Disease Detected by Liquid Biopsy

NCT05408897 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05408897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05408897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Minimal Residual Disease Detected by Liquid Biopsy
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2022
Completion date
April 30, 2028
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumors, minimal residual disease